What the Studies Say
Curious minds deserve real answers. Here's what researchers are finding.
The Endocannabanoid System
Di Marzo, V., et al. (1998)
“Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action”
📍 Trends in Neurosciences
👉 Read the paper →
🧬 Why it matters: Scientists discovered that the brain makes its own cannabis-like compounds—called endocannabinoids—that help regulate how brain cells communicate. They work a lot like THC, influencing mood, stress, and neurotransmitter balance.
Pertwee, R. G. (2008)
“The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-THC, cannabidiol and delta9-THCV”
📍 British Journal of Pharmacology
👉 Read the article →
🧠 Why it matters: This study breaks down how different cannabinoids interact with ECS receptors. It shows that THC, CBD, and other compounds each “tune” the ECS in different ways—helping explain why full-spectrum formulations feel different than isolates.
Mackie, K. (2008)
“Cannabinoid receptors: where they are and what they do”
📍 Journal of Neuroendocrinology
👉 Read it here →
🧭 Why it matters: This is a map of where ECS receptors live in your body (spoiler: they’re everywhere—brain, gut, skin, immune system). It helps explain how cannabis and the ECS impact so many things at once, from inflammation to stress.
Lu, H. C., & Mackie, K. (2016)
“An introduction to the endogenous cannabinoid system”
📍 Biological Psychiatry
👉 Full text →
📘 Why it matters: Think of this one as your ECS 101 course. It lays out how the system works, how it helps maintain balance (homeostasis), and why it’s crucial for both physical and mental well-being.
Zou, S., & Kumar, U. (2018)
“Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system”
📍 International Journal of Molecular Sciences
👉 Full article →
🧩 Why it matters: This paper dives into how ECS signaling affects brain function—think pain, memory, mood, and neuroprotection. It’s the science behind why cannabinoids might help with things like anxiety, PTSD, or even neurodegenerative conditions.
The Entourage Effect
Ben-Shabat et al. (1998)
“An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-AG activity”
📍 European Journal of Pharmacology
👉 Read the paper
🧠 Why it matters: This is the OG paper that coined the term “entourage effect.” It showed that naturally occurring compounds in the body can amplify the effects of endocannabinoids—laying the groundwork for the idea that cannabinoids and terpenes work better together than alone.
Russo, Ethan B. (2011)
“Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects”
📍 British Journal of Pharmacology
👉 Read the article
🌱 Why it matters: This is the go-to scientific breakdown of how THC, CBD, and terpenes like myrcene or limonene may work synergistically. It’s a foundational piece for anyone building a full-spectrum or flavor-forward cannabis product.
Pamplona, F. A., et al. (2018)
“Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy”
📍 Frontiers in Neurology
👉 Read the meta-analysis
📊 Why it matters: This meta-analysis found that patients responded better to whole-plant CBD extracts than isolated CBD—clinical proof that the “entourage” of compounds makes a real difference.
Carmona-Hidalgo, B., et al. (2023)
“The Neurotherapeutic Arsenal in Cannabis sativa: Insights into Anti-Neuroinflammatory and Neuroprotective Activity and Potential Entourage Effects”
📍 Molecules
👉 View the study
🧬 Why it matters: This study explores how various compounds in Cannabis sativa—including cannabinoids, terpenes, and flavonoids—may work together to reduce brain inflammation and protect against neurodegenerative damage. It adds strong support to the entourage effect, especially in the context of mental health and neurological wellness.
Baron, Eric P. (2018)
“Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis”
📍 Current Neurology and Neuroscience Reports
👉 Read the article
💡 Why it matters: Explores how not just cannabinoids, but also terpenes and flavonoids work together to deliver the full effects of cannabis. Great for brands focused on holistic or whole-plant approaches.
Terpenes
Russo, Ethan B. (2011)
“Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects”
📍 British Journal of Pharmacology
🌱 Why it matters: This foundational paper lays out how terpenes like myrcene, limonene, and pinene may work with cannabinoids to shape how cannabis feels—relaxing, energizing, calming, etc. Major support for the entourage effect.
Ferber, S. G., et al. (2020)
“The ‘entourage effect’: Terpenes coupled with cannabinoids for the treatment of mood and anxiety disorders”
📍 Current Neuropharmacology
🧬 Why it matters: This study supports the idea that combining terpenes with cannabinoids may boost therapeutic effects—especially for mood, stress, and anxiety. Great ammo for functional formulations.
Baron, Eric P. (2018)
“Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis”
📍 Current Neurology and Neuroscience Reports
💡 Why it matters: This study digs into the therapeutic potential of not just cannabinoids, but terpenes and flavonoids—making the case for full-spectrum, whole-plant formulations.
Booth, J. K., & Bohlmann, J. (2019)
“Terpenes in Cannabis sativa – From plant genome to humans”
📍 Plant Science
🧪 Why it matters: A look at the science behind terpene biosynthesis and how these compounds impact both plant biology and human experience. Great for understanding how terpenes are formed and why they matter beyond aroma.
Sommano, S. R., et al. (2020)
“The Cannabis Terpenes”
📍 Molecules
📊 Why it matters: This study provides strong scientific context for why terpenes are more than just smell—they help define the experience and therapeutic potential of each cannabis strain. It supports using terpene profiles as a tool in product development, consumer education, and whole-plant wellness strategies.
CB1 vs CB2
Zou, S., & Kumar, U. (2018)
Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System
📍 International Journal of Molecular Sciences
👉 Read the study
📊 Why it matters: This review clearly explains how CB1 dominates in the brain and CB2 in the immune system, making it a go-to primer on where and how these receptors work.
Turcotte, C., Blanchet, M.-R., Laviolette, M., & Flamand, N. (2016)
The CB2 Receptor and Its Role as a Regulator of Inflammation
📍 Cellular and Molecular Life Sciences
👉 Read the study
📊 Why it matters: Details how CB2 modulates inflammation, especially in chronic disease.
Pertwee, R. G. (2008)
The Diverse CB1 and CB2 Receptor Pharmacology of Three Plant Cannabinoids
📍 British Journal of Pharmacology
👉 Read the study
📊 Why it matters: Covers how THC and CBD interact differently with CB1 and CB2.
Cabral, G. A., Raborn, E. S., Griffin, L., Dennis, J., & Marciano-Cabral, F. (2008)
CB2 Receptors in the Brain: Role in Central Immune Function
📍 British Journal of Pharmacology
👉 Read the study
📊 Why it matters: This study explores CB2’s lesser-known role inside the brain, especially in microglia — great for busting the “CB2 = not in brain” myth.
Leishman, E., Bradshaw, H. B. (2023)
Cannabinoid Receptor 1 and 2 Expression in the Human Central and Peripheral Nervous System
📍 Cannabis and Cannabinoid Research
👉 Read the study
📊 Why it matters: This study provides the most comprehensive mapping to date of CB1 and CB2 receptor expression across both the central and peripheral nervous systems in humans — not animals. That’s huge, because a lot of past assumptions were based on rodent models.
Methods of Delivery
Grotenhermen, F. (2003)
Pharmacokinetics and Pharmacodynamics of Cannabinoids
📍 Clinical Pharmacokinetics
👉 Read the study
📊 Why it matters: This study explains how different methods of cannabis consumption impact absorption, onset time, and overall effects — foundational info for understanding delivery differences.
Huestis, M. A. (2007)
Human Cannabinoid Pharmacokinetics
📍 Chemistry & Biodiversity
👉 Read the study
📊 Why it matters: Focuses specifically on how inhalation, oral, and sublingual methods lead to wildly different blood concentration levels.
Lucas, C. J., Galettis, P., & Schneider, J. (2018)
The Pharmacokinetics and the Pharmacodynamics of Cannabinoids
📍 British Journal of Clinical Pharmacology
👉 Read the study
📊 Why it matters: Compares smoking, vaping, oral, and sublingual administration — shows why inhalation is fast but short-lived, while edibles take longer but stick around.
Millar, S. A., Stone, N. L., Yates, A. S., & O’Sullivan, S. E. (2018)
A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans
📍 Frontiers in Pharmacology
👉 Read the study
📊 Why it matters: Focuses on CBD specifically, but beautifully explains why method of administration matters so much for absorption and therapeutic effect.
Zgair, A., Wong, J. C. M., Lee, J. B., Mistry, J., Sivak, O., Wasan, K. M., & Hennig, I. M. (2016)
Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabinoid-based medicines
📍 European Journal of Clinical Pharmacology
👉 Read the study
📊 Why it matters: This study highlights how oral delivery (like edibles) is highly influenced by digestive processes and dietary fats. It reinforces how different ingestion methods — and even what you eat them with — can drastically change how much and how fast cannabinoids are absorbed.
Tolerance
Piscura, M. K., Henderson-Redmond, A. N., Barnes, R. C., Mitra, S., Guindon, J., & Morgan, D. J. (2023)
Mechanisms of cannabinoid tolerance
📍 Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
👉 Read the study
📊 Why it matters: This detailed review unpacks how tolerance develops on a molecular level—highlighting CB1 receptor desensitization, downregulation, and altered intracellular signaling. It’s a go-to resource for understanding why frequent cannabinoid use leads to reduced effects over time and how the body tries to compensate.
González, S., Cebeira, M., & Fernández-Ruiz, J. (2005)
Cannabinoid tolerance and dependence: A review of studies in laboratory animals
📍 Pharmacology, Biochemistry and Behavior
👉 Read the study
📊 Why it matters: This review compiles preclinical research showing how repeated cannabinoid exposure leads to tolerance and dependence in animal models. It highlights behavioral and biochemical changes, including CB1 receptor downregulation, reduced G-protein coupling, and withdrawal effects—making it a valuable source for understanding the early science behind cannabinoid adaptation in the body.
Battistella, G., Fornari, E., Annoni, J.-M., Chtioui, H., Dao, K., Fabritius, M., Favrat, B., Mall, J.-F., Maeder, P., & Giroud, C. (2014)
Long-Term Effects of Cannabis on Brain Structure
📍 Neuropsychopharmacology
👉 Read the study
📊 Why it matters: This neuroimaging study found that regular cannabis use is associated with structural changes in brain regions rich in CB1 receptors, such as the hippocampus and amygdala. These areas are tied to memory, emotion, and motivation—so long-term cannabis use may alter the brain's architecture, which could interact with tolerance mechanisms and cognitive function over time.
Wilkerson, J. L., Schulze, D. R., & McMahon, L. R. (2021)
Tolerance and dependence to Δ9-tetrahydrocannabinol in rhesus monkeys: Activity assessments
📍 Drug and Alcohol Dependence
👉 Read the study
📊 Why it matters: This preclinical study provides direct evidence of THC tolerance and physical dependence in rhesus monkeys, showing reduced responsiveness to THC’s activity-suppressing effects over time. It also documented withdrawal-like symptoms, reinforcing that tolerance isn’t just about needing more to feel the same—it reflects deep neurological adaptations to sustained cannabinoid exposure.
Mason, N. L., Theunissen, E. L., Hutten, N., Tse, D. H. Y., Toennes, S. W., Jansen, J. F. A., Stiers, P., & Ramaekers, J. G. (2021)
Reduced responsiveness of the reward system is associated with tolerance to cannabis impairment in chronic users
📍 Addiction Biology
👉 Read the study
📊 Why it matters: This fMRI study shows that chronic cannabis users have a blunted response in brain reward regions—even when under the influence. It’s one of the strongest pieces of evidence linking behavioral tolerance to measurable neural changes, especially in how the brain processes motivation and reward under cannabis.
Minor Cannabinoids
Stone, N. L., Murphy, A. J., England, T. J., & O’Sullivan, S. E. (2020)
A systematic review of minor phytocannabinoids with promising neuroprotective potential
📍 British Journal of Pharmacology
👉 Read the study
📊 Why it matters: This review highlights several minor cannabinoids—including CBG, CBDV, THCV, and CBC—for their neuroprotective effects in preclinical models. It explores mechanisms like anti-inflammatory action, antioxidant effects, and interaction with non-cannabinoid receptors.
McPartland, J. M., Duncan, M., Di Marzo, V., & Pertwee, R. G. (2015)
Are cannabidiol and Δ9‐tetrahydrocannabivarin negative modulators of the endocannabinoid system?
📍 British Journal of Pharmacology
👉 Read the study
📊 Why it matters: Focuses on CBD and THCV as modulators, not just binders, of the ECS—highlighting how these cannabinoids may counteract or fine-tune the effects of THC and other compounds. That’s critical for formulating functional blends.
Sepulveda, D. E., Vrana, K. E., Kellogg, J. J., Bisanz, J. E., Desai, D., Graziane, N. M., & Raup-Konsavage, W. M. (2023)
The Potential of Cannabichromene (CBC) as a Therapeutic Agent
📍 Cannabis and Cannabinoid Research
👉 Read the study
📊 Why it matters: This recent study provides one of the most detailed breakdowns of CBC's pharmacological potential, including its anti-inflammatory, analgesic, and neuroprotective effects. It also examines CBC’s mechanisms beyond the endocannabinoid system, making it a standout candidate for therapeutic formulations that don’t rely on CB1/CB2 activation.
Bolognini, D., Rock, E. M., Cluny, N. L., et al. (2013)
Cannabidiolic acid prevents nausea and vomiting in a rat model of chemotherapy-induced nausea
📍 British Journal of Pharmacology
👉 Read the study
📊 Why it matters: This study highlights CBDA’s powerful anti-nausea effects—even stronger than CBD in some models. It also shows CBDA acts via serotonin receptors, expanding our understanding of how minor cannabinoids work beyond the ECS.
Lacerda, M., Carona, A., Castanheira, S., Falcão, A., Bicker, J., & Fortuna, A. (2023)
Pharmacokinetics of Non-Psychotropic Phytocannabinoids
📍 Pharmaceuticals
👉 Read the study
📊 Why it matters: This study dives deep into how non-psychotropic cannabinoids like CBD, CBG, CBC, and CBDV are absorbed, distributed, metabolized, and excreted. It highlights their poor oral bioavailability and how factors like formulation and delivery method dramatically affect therapeutic outcomes
